1 2

Tirzepatide

Tirzepatide

Dual-Chamber Pen

Tirzepatide Peptide Pen is available in 20 mg and 40 mg strengths and contains a dual GIP and GLP-1 receptor agonist. Tirzepatide has attracted significant research interest after clinical studies reported substantial reductions in body weight alongside improvements in blood sugar control and other metabolic measures.

What makes Tirzepatide distinctive is that it combines GIP and GLP-1 receptor activity within a single 39-amino-acid peptide. Researchers continue to investigate how this dual action influences appetite, glucose regulation, insulin response and energy balance.

PCP’s proprietary Dual-Chamber Technology keeps the lyophilised Tirzepatide separate from the bacteriostatic water until activation.

For laboratory research use only. Not intended for human or veterinary use.

Strength
3.990,00 CZK
3.990,00 CZK
Sale Sold out
Taxes included. Shipping calculated at checkout.
Fast, Tracked Shipping
Secure Checkout
COA Available With Lot
Expert Support
Product Details

The Tirzepatide Dual-Chamber Research Pen is supplied in a preloaded format that keeps the lyophilised Tirzepatide powder and diluent physically separated until preparation. This allows the components to remain unmixed during storage and transport.

Each pen is clearly identified and professionally packaged to support product protection, straightforward handling and accurate strength selection within qualified research environments.

Product highlights:

• Dual-chamber configuration with separately contained Tirzepatide powder and diluent
• Supplied unmixed until laboratory preparation
• Available in 20 mg and 40 mg strengths
• Provides 100 dial units in total
• One complete dual-chamber cartridge per pen
• Five 32G × 4 mm needle tips included
• Protective packaging for storage and transport
• Certificate of Analysis (COA) available

Technical specifications, dial-unit information, storage requirements and handling guidance are provided to support product identification and responsible laboratory use.

Technical Specifications
Intended Use
For laboratory research use only. Not for human or veterinary use.
Shipping Condition
Securely packaged for transport with tracked delivery.
Storage Temperature
Unopened/unmixed: store refrigerated at 2–8°C. After mixing: store refrigerated at 2–8°C. Do not freeze. Protect from light.
Presentation
One pre-filled double-chamber research pen containing unmixed components, supplied with three 32G × 4 mm needle tips
Form
Lyophilized peptide powder and diluent maintained in separate chambers
Compound Identity
Compound: Tirzepatide

Compound type: Synthetic 39-amino-acid peptide

Research classification: Dual GIPR and GLP-1R agonist investigated in connection with incretin-receptor pharmacology, glucose-dependent signalling, endocrine communication and metabolic regulation

Refer to the applicable product and batch documentation for verified analytical and chemical identity information.
Pen Specifications

Each pen contains a 1 mL cartridge. The amount represented by one dial unit depends on the selected pen strength. The tables below show the corresponding values for each available strength.

Pen Specifications
Pen strength Cartridge 1 dial unit
10 mg 1 mL 0.1 mg
20 mg 1 mL 0.2 mg
40 mg 1 mL 0.4 mg

Dial-Unit Conversion Reference

The table shows the amount represented by each listed dial setting for the available pen strengths.

Dial-unit reference by pen strength
Dial units 10 mg 20 mg 40 mg
1 0.1 mg 0.2 mg 0.4 mg
4 0.4 mg 0.8 mg 1.6 mg
5 0.5 mg 1.0 mg 2.0 mg
10 1.0 mg 2.0 mg 4.0 mg
20 2.0 mg 4.0 mg 8.0 mg
40 4.0 mg 8.0 mg 16.0 mg

Research-use information: Dial-unit values are provided solely for product identification, quantitative laboratory planning and documentation. They are not administration or clinical dosing instructions.

Storage & Handling

Recommended storage: Unopened/unmixed: store refrigerated at 2–8°C. After mixing: store refrigerated at 2–8°C. Do not freeze. Protect from light.

Protect the product from light and moisture and minimise unnecessary exposure to room temperature.

Complete storage and handling guidance is provided in the product information section below.

Research Use Only

All Pencell Peptide (PCP) products are supplied exclusively for laboratory research use by qualified professionals. They are not intended for human or veterinary use, consumption, personal use, medical, therapeutic, or diagnostic applications. Customers are responsible for lawful purchase, storage, handling, use, and disposal in accordance with applicable regulations and approved laboratory procedures.

View full details

Protected by Design

Peptide and diluent remain separate until preparation

≥98% Purity

HPLC verified for research grade quality

Controlled Conditions

Prepared with a focus on consistency and research quality

Certificate of Analysis

Provided with Every Lot

Scientific Overview

Scientific Background

Tirzepatide is a synthetic peptide composed of 39 amino acids and developed from a GIP-based sequence. The arrangement and modification of these amino acids determine how the peptide interacts with its target receptors and how long it remains biologically active.

Tirzepatide is a dual receptor agonist, activating both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). These receptors are involved in interconnected processes including glucose regulation, insulin signalling, appetite and energy balance. Combining both activities within a single peptide is a defining feature of Tirzepatide.

Its molecular structure also includes specific amino-acid modifications and a fatty-diacid side chain that promotes albumin binding, helping protect the peptide from rapid breakdown and extending its activity. This makes Tirzepatide particularly useful for studying how molecular design influences receptor activity and duration of action.

Research continues to examine how coordinated GIP and GLP-1 signalling differs from selective GLP-1 activation, including its relationship with adipose tissue, hepatic pathways and wider cardiometabolic mechanisms.

This information is provided as general scientific background for laboratory research purposes.
Research Context

Research Applications

Areas examined within controlled laboratory research.

Tirzepatide combines GIP and GLP-1 receptor activity within a single peptide, distinguishing it from compounds that target GLP-1 alone. Clinical research has reported substantial changes in body weight, blood sugar control and other metabolic measures, creating strong interest in how these two incretin pathways work together.

Researchers continue to investigate how Tirzepatide’s dual-receptor activity influences appetite signalling, insulin response, glucose regulation, energy balance and fat metabolism, as well as broader metabolic processes involving the liver and adipose tissue.

Current areas of scientific investigation include:

  1. Dual Incretin-Receptor Pharmacology (Tirzepatide)

    Investigation of Tirzepatide’s combined activity at GIPR and GLP-1R, including receptor binding, activation and downstream signalling under controlled experimental conditions.

  2. Glucose-Dependent Signalling (Tirzepatide)

    Study of cellular and molecular pathways associated with glucose-dependent incretin signalling and coordinated GIPR and GLP-1R activity.

  3. Endocrine Communication (Tirzepatide)

    Research into the relationship between dual incretin-receptor activation and interconnected endocrine signalling networks in cellular, preclinical and comparative models.

  4. Energy-Regulation Pathways (Tirzepatide)

    Investigation of signalling mechanisms associated with energy balance, nutrient sensing and metabolic regulation across controlled experimental systems.

  5. Adipose-Tissue Signalling (Tirzepatide)

    Study of Tirzepatide in adipocyte and adipose-tissue models, including pathways related to cellular signalling, substrate utilisation and metabolic activity.

  6. Hepatic Metabolic Pathways (Tirzepatide)

    Research examining hepatic signalling, glucose and lipid metabolism, and the interaction between liver-associated pathways and dual incretin-receptor activity.

  7. Comparative Receptor Activity (Tirzepatide)

    Comparative evaluation of Tirzepatide alongside selective GLP-1 receptor agonists and other multi-receptor compounds to investigate differences in receptor engagement, functional activity and downstream biological responses.

Clinical studies of Tirzepatide have reported substantial effects on body weight and blood sugar control, with additional changes observed across several measures of metabolic health. These findings have made its combined GIP and GLP-1 receptor activity an important area of ongoing research.

Researchers continue to investigate how this dual action influences appetite, insulin response, glucose regulation, energy balance and fat metabolism, and whether targeting two incretin pathways produces biological responses that differ from selective GLP-1 receptor activation.

Together, this research is helping build a clearer understanding of how GIP and GLP-1 signalling work together and how Tirzepatide’s molecular design contributes to the effects observed in clinical and experimental studies.

For laboratory research purposes only. Not intended for human or veterinary use.

Important Notice Research Use Only View complete notice

All products supplied by Pencell Peptide (PCP), including its dual-chamber peptide research pens, are intended strictly for laboratory research purposes only.

These products are not intended for human or animal consumption, medical or veterinary use, therapeutic applications, diagnostic procedures or any other clinical purpose.

Customers are responsible for complying with all applicable laws, regulations and institutional requirements governing the purchase, possession, handling, storage and use of peptide research materials.

Read the complete Research Use Only notice .